Home > Press Releases > Radioligand Therapies (RLT) Market

Radioligand Therapies (RLT) Market Likely to Surpass USD 31.4 Billion by 2035

Report Code: HC-305  |  Published in: Aug 2026, By MarketGenics  |  Number of pages: 316
Get PDF
Buy

Global Radioligand Therapies (RLT) Market Forecast 2035:

According to the report, the global radioligand therapies (RLT) market is likely to grow from USD 6.4 Billion in 2025 to USD 31.4 Billion in 2035 at a highest CAGR of 12.7% during the time period. The radioligand therapies (RLT) market is being propelled by the rising incidence of cancer, growing use of precision oncology, and the need for targeted cancer treatments. RLT allows targeted delivery of therapeutic radioactive agents to the molecular target of a tumour enabling the effective treatment of the tumour while limiting exposure to normal tissues. Growing clinical data and treatment efficacy are raising both physician confidence and patient acceptance of these treatments.

Providing more precise identification of patients and treatment selection, especially in theranostic strategies that integrate molecular imaging and targeted therapy, is bolstered by the increasing role that companion imaging has played in diagnostic imaging. New applications of radioligands in new solid tumors and new cancer types are providing greater commercial opportunities. Capacity building efforts in the radiopharmaceutical industry, isotope sourcing, and creation of treatment centers and supply chain infrastructure are enhancing access.

The precision of treatment is further enhanced through technological innovations in radionuclide production, radioligand development and in personalized dosing. Innovation, expanded therapeutic applications and strengthening the competitive landscape are accelerating due to the increasing investments in pharmaceutical and biotechnology pipelines for RLT. The RLT market is expected to grow significantly with the increasing clinical applications, capabilities of precision treatment, and infrastructure for radiopharmaceuticals.

“Key Driver, Restraint, and Growth Opportunity Shaping the Global Radioligand Therapies (RLT) Market

Adoption of RLT is being facilitated by the increasing use of individualized dosimetry to support treatment planning based on the patient specific tumor uptake and radiation exposure, together with the tolerance of the organs. This can result in better dose optimization, safer and more accurate administration in heterogeneous patient populations, and better treatment safety.

Stringent radiation-safety requirements create operational and infrastructure challenges for RLT providers. Implementation of specialized shielding, waste handling, controlled handling procedures, trained personnel, and dedicated facilities make operations more complex and capital intensive, which may hinder the adoption of the system by smaller healthcare centers.

The generation of new theranostic radionuclide pairs offers an opportunity to extend the range of targets to be treated by the RLT. Combining diagnostic and therapeutic isotopes to visualize the targets, select patients, plan treatments, track the response to therapy, and develop therapies for additional cancers offers a complete precision-medicine strategy.

Regional Analysis of Global Radioligand Therapies (RLT) Market

  • North America is the most demanding region for Radioligand Therapies (RLT) attributed to the presence of specialized cancer centers, high nuclear medicine specialists and cancer oncology and molecular imaging integration. There is also an improvement in the use of the advanced PET/CT and SPECT/CT facilities in the region, which enable efficient theranostic workflows.
  • Asia Pacific is witnessing high growth rates in the RLT market due to the formation of a robust oncology infrastructure, the rising number of nuclear medicine facilities, and the increasing use of advanced diagnostic imaging for targeted radiotherapies. Growing and ageing population makes a growing pool of cancer patients available to the region, and investments in healthcare systems and development of cancer treatment centers have bolstered the region's capabilities.
  • The RLT market is showing strong growth in Europe, as theranostic capabilities are growing and there is a fat bank of expertise and development of the production of radiopharmaceutical infrastructure. Targeted radionuclide treatment is increasingly being implemented in the clinic and ongoing investment in the production of isotopes is helping build capacity across the region.

Key players in the global radioligand therapies (RLT) market include prominent companies such as Actinium Pharmaceuticals, Inc., AstraZeneca, Bayer AG, Bristol Myers Squibb, Clarity Pharmaceuticals, Curium Pharma Ltd., Eli Lilly and Company, Perspective Therapeutics, ITM Isotope Technologies Munich SE, Lantheus Holdings, Novartis AG, POINT Biopharma Global Inc., RadioMedix Inc., Telix Pharmaceuticals Limited, Y-mAbs Therapeutics, Inc., Other Key Players.

The global radioligand therapies (RLT) market has been segmented as follows:

Global Radioligand Therapies (RLT) Market Analysis, by Type

  • Oncology Diagnosis
  • Oncology Therapy
  • Non-oncology (emerging)

Global Radioligand Therapies (RLT) Market Analysis, by Radioisotope

  • Alpha Emitters
  • Beta Emitters
  • Gamma Emitters (Imaging)

Global Radioligand Therapies (RLT) Market Analysis, by Targeting Vector

  • Peptides
  • Small Molecules
  • Monoclonal Antibodies
  • Antibody Fragments

Global Radioligand Therapies (RLT) Market Analysis, by Product Class

  • PSMA-targeted Therapies
  • Somatostatin Receptor-targeted Therapies
  • Other Targeted Constructs

Global Radioligand Therapies (RLT) Market Analysis, by Cancer Type

  • Prostate Cancer
  • Neuroendocrine Tumors (NETs)
  • Thyroid Cancer
  • Lymphoma/Leukemia
  • Bone Metastases
  • Other Solid Tumors

Global Radioligand Therapies (RLT) Market Analysis, by Distribution Channel

  • Centralized Radiopharmacies
  • Point-of-care Manufacturing
  • Direct Hospital Supply

Global Radioligand Therapies (RLT) Market Analysis, by End User

  • Hospitals
  • Diagnostic Imaging Centers
  • Specialty Cancer Treatment Centers
  • Academic & Research Institutes
  • CMOs/Radiopharmacies

Global Radioligand Therapies (RLT) Market Analysis, by Region

  • North America
  • Europe
  • Asia Pacific
  • Middle East
  • Africa
  • South America

About Us

MarketGenics is a global market research and management consulting company empowering decision makers from startups, Fortune 500 companies, non-profit organizations, universities and government institutions. Our main goal is to assist and partner organizations to make lasting strategic improvements and realize growth targets. Our industry research reports are designed to provide granular quantitative information, combined with key industry insights, aimed at assisting sustainable organizational development.

We serve clients on every aspect of strategy, including product development, application modeling, exploring new markets and tapping into niche growth opportunities.

Contact US

USA Address:

800 N King Street Suite 304 #4208 Wilmington, DE 19801 United States.

+1(302)303-2617

info@marketgenics.co

India Address:

3rd floor, Indeco Equinox, Baner Road, Baner, Pune, Maharashtra 411045 India.

sales@marketgenics.co

 

Table of Contents

  • 1. Research Methodology and Assumptions
    • 1.1. Definitions
    • 1.2. Research Design and Approach
    • 1.3. Data Collection Methods
    • 1.4. Base Estimates and Calculations
    • 1.5. Forecasting Models
      • 1.5.1. Key Forecast Factors & Impact Analysis
    • 1.6. Secondary Research
      • 1.6.1. Open Sources
      • 1.6.2. Paid Databases
      • 1.6.3. Associations
    • 1.7. Primary Research
      • 1.7.1. Primary Sources
      • 1.7.2. Primary Interviews with Stakeholders across Ecosystem
  • 2. Executive Summary
    • 2.1. Global Radioligand Therapies (RLT) Market Outlook
      • 2.1.1. Radioligand Therapies (RLT) Market Size Value (US$ Bn), and Forecasts, 2021-2035
      • 2.1.2. Compounded Annual Growth Rate Analysis
      • 2.1.3. Growth Opportunity Analysis
      • 2.1.4. Segmental Share Analysis
      • 2.1.5. Geographical Share Analysis
    • 2.2. Market Analysis and Facts
    • 2.3. Supply-Demand Analysis
    • 2.4. Competitive Benchmarking
    • 2.5. Go-to- Market Strategy
      • 2.5.1. Customer/ End-use Industry Assessment
      • 2.5.2. Growth Opportunity Data, 2026-2035
        • 2.5.2.1. Regional Data
        • 2.5.2.2. Country Data
        • 2.5.2.3. Segmental Data
      • 2.5.3. Identification of Potential Market Spaces
      • 2.5.4. GAP Analysis
      • 2.5.5. Potential Attractive Price Points
      • 2.5.6. Prevailing Market Risks & Challenges
      • 2.5.7. Preferred Sales & Marketing Strategies
      • 2.5.8. Key Recommendations and Analysis
      • 2.5.9. A Way Forward
  • 3. Industry Data and Premium Insights
    • 3.1. Global Healthcare & Pharmaceutical Industry Overview, 2025
      • 3.1.1. Healthcare & Pharmaceutical Ecosystem Analysis
      • 3.1.2. Key Trends for Healthcare & Pharmaceutical Industry
      • 3.1.3. Regional Distribution for Healthcare & Pharmaceutical Industry
    • 3.2. Supplier Customer Data
    • 3.3. Technology Roadmap and Developments
  • 4. Market Overview
    • 4.1. Market Dynamics
      • 4.1.1. Drivers
        • 4.1.1.1. Expanding RLT Approvals and Indications
        • 4.1.1.2. Rising Prevalence of Prostate Cancer and NETs
        • 4.1.1.3. Growing Adoption of Precision Oncology and Theranostics
      • 4.1.2. Restraints
        • 4.1.2.1. Limited Radioisotope Supply and Production Capacity
        • 4.1.2.2. High Infrastructure, Manufacturing, and Logistics Costs
    • 4.2. Key Trend Analysis
    • 4.3. Regulatory Framework
      • 4.3.1. Key Regulations, Norms, and Subsidies, by Key Countries
      • 4.3.2. Tariffs and Standards
      • 4.3.3. Impact Analysis of Regulations on the Market
    • 4.4. Ecosystem Analysis
    • 4.5. Porter’s Five Forces Analysis
    • 4.6. PESTEL Analysis
    • 4.7. Global Radioligand Therapies (RLT) Market Demand
      • 4.7.1. Historical Market Size – Value (US$ Bn), 2020-2024
      • 4.7.2. Current and Future Market Size - Value (US$ Bn), 2026–2035
        • 4.7.2.1. Y-o-Y Growth Trends
        • 4.7.2.2. Absolute $ Opportunity Assessment
  • 5. Competition Landscape
    • 5.1. Competition structure
      • 5.1.1. Fragmented v/s consolidated
    • 5.2. Company Share Analysis, 2025
      • 5.2.1. Global Company Market Share
      • 5.2.2. By Region
        • 5.2.2.1. North America
        • 5.2.2.2. Europe
        • 5.2.2.3. Asia Pacific
        • 5.2.2.4. Middle East
        • 5.2.2.5. Africa
        • 5.2.2.6. South America
    • 5.3. Product Comparison Matrix
      • 5.3.1. Specifications
      • 5.3.2. Market Positioning
      • 5.3.3. Pricing
  • 6. Global Radioligand Therapies (RLT) Market Analysis, by Type
    • 6.1. Key Segment Analysis
    • 6.2. Radioligand Therapies (RLT) Market Size Value (US$ Bn), Analysis, and Forecasts, by Fiber Type, 2021-2035
      • 6.2.1. Oncology Diagnosis
      • 6.2.2. Oncology Therapy
      • 6.2.3. Non-oncology (emerging)
  • 7. Global Radioligand Therapies (RLT) Market Analysis, by Radioisotope
    • 7.1. Key Segment Analysis
    • 7.2. Radioligand Therapies (RLT) Market Size Value (US$ Bn), Analysis, and Forecasts, by Radioisotope, 2021-2035
      • 7.2.1. Lutetium-177 (Lu-177)
      • 7.2.2. Actinium-225 (Ac-225)
      • 7.2.3. Gallium-68 (Ga-68)
      • 7.2.4. Yttrium-90 (Y-90)
      • 7.2.5. Iodine-131 (I-131)
      • 7.2.6. Copper-64/Copper-67
      • 7.2.7. Technetium-99m
      • 7.2.8. Radium-223
      • 7.2.9. Others (Terbium-161, Astatine-211, Bismuth-213, etc.)
  • 8. Global Radioligand Therapies (RLT) Market Analysis, by Radiation Type
    • 8.1. Key Segment Analysis
    • 8.2. Radioligand Therapies (RLT) Market Size Value (US$ Bn), Analysis, and Forecasts, by Radiation Type, 2021-2035
      • 8.2.1. Alpha Emitters
      • 8.2.2. Beta Emitters
      • 8.2.3. Gamma Emitters (Imaging)
  • 9. Global Radioligand Therapies (RLT) Market Analysis, by Targeting Vector
    • 9.1. Key Segment Analysis
    • 9.2. Radioligand Therapies (RLT) Market Size Value (US$ Bn), Analysis, and Forecasts, by Targeting Vector, 2021-2035
      • 9.2.1. Peptides
      • 9.2.2. Small Molecules
      • 9.2.3. Monoclonal Antibodies
      • 9.2.4. Antibody Fragments
  • 10. Global Radioligand Therapies (RLT) Market Analysis and Forecasts, by Product Class
    • 10.1. Key Findings
    • 10.2. Radioligand Therapies (RLT) Market Size Value (US$ Bn), Analysis, and Forecasts, by Product Class, 2021-2035
      • 10.2.1. PSMA-targeted Therapies
      • 10.2.2. Somatostatin Receptor-targeted Therapies
      • 10.2.3. Other Targeted Constructs
  • 11. Global Radioligand Therapies (RLT) Market Analysis and Forecasts, by Cancer Type
    • 11.1. Key Findings
    • 11.2. Radioligand Therapies (RLT) Market Size Value (US$ Bn), Analysis, and Forecasts, by Cancer Type, 2021-2035
      • 11.2.1. Prostate Cancer
      • 11.2.2. Neuroendocrine Tumors (NETs)
      • 11.2.3. Thyroid Cancer
      • 11.2.4. Lymphoma/Leukemia
      • 11.2.5. Bone Metastases
      • 11.2.6. Other Solid Tumors
  • 12. Global Radioligand Therapies (RLT) Market Analysis and Forecasts, by Distribution Channel
    • 12.1. Key Findings
    • 12.2. Radioligand Therapies (RLT) Market Size Value (US$ Bn), Analysis, and Forecasts, by Distribution Channel, 2021-2035
      • 12.2.1. Centralized Radiopharmacies
      • 12.2.2. Point-of-care Manufacturing
      • 12.2.3. Direct Hospital Supply
  • 13. Global Radioligand Therapies (RLT) Market Analysis and Forecasts, by End User
    • 13.1. Key Findings
    • 13.2. Radioligand Therapies (RLT) Market Size Value (US$ Bn), Analysis, and Forecasts, by End User, 2021-2035
      • 13.2.1. Hospitals
      • 13.2.2. Diagnostic Imaging Centers
      • 13.2.3. Specialty Cancer Treatment Centers
      • 13.2.4. Academic & Research Institutes
      • 13.2.5. CMOs/Radiopharmacies
  • 14. Global Radioligand Therapies (RLT) Market Analysis and Forecasts, by Region
    • 14.1. Key Findings
    • 14.2. Radioligand Therapies (RLT) Market Size Value (US$ Bn), Analysis, and Forecasts, by Region, 2021-2035
      • 14.2.1. North America
      • 14.2.2. Europe
      • 14.2.3. Asia Pacific
      • 14.2.4. Middle East
      • 14.2.5. Africa
      • 14.2.6. South America
  • 15. North America Radioligand Therapies (RLT) Market Analysis
    • 15.1. Key Segment Analysis
    • 15.2. Regional Snapshot
    • 15.3. North America Radioligand Therapies (RLT) Market Size- Value (US$ Bn), Analysis, and Forecasts, 2021-2035
      • 15.3.1. Type
      • 15.3.2. Radioisotope
      • 15.3.3. Radiation Type
      • 15.3.4. Targeting Vector
      • 15.3.5. Product Class
      • 15.3.6. Cancer Type
      • 15.3.7. Distribution Channel
      • 15.3.8. End User
      • 15.3.9. Country
        • 15.3.9.1. USA
        • 15.3.9.2. Canada
        • 15.3.9.3. Mexico
    • 15.4. USA Radioligand Therapies (RLT) Market
      • 15.4.1. Country Segmental Analysis
      • 15.4.2. Type
      • 15.4.3. Radioisotope
      • 15.4.4. Radiation Type
      • 15.4.5. Targeting Vector
      • 15.4.6. Product Class
      • 15.4.7. Cancer Type
      • 15.4.8. Distribution Channel
      • 15.4.9. End User
    • 15.5. Canada Radioligand Therapies (RLT) Market
      • 15.5.1. Country Segmental Analysis
      • 15.5.2. Type
      • 15.5.3. Radioisotope
      • 15.5.4. Radiation Type
      • 15.5.5. Targeting Vector
      • 15.5.6. Product Class
      • 15.5.7. Cancer Type
      • 15.5.8. Distribution Channel
      • 15.5.9. End User
    • 15.6. Mexico Radioligand Therapies (RLT) Market
      • 15.6.1. Country Segmental Analysis
      • 15.6.2. Type
      • 15.6.3. Radioisotope
      • 15.6.4. Radiation Type
      • 15.6.5. Targeting Vector
      • 15.6.6. Product Class
      • 15.6.7. Cancer Type
      • 15.6.8. Distribution Channel
      • 15.6.9. End User
  • 16. Europe Radioligand Therapies (RLT) Market Analysis
    • 16.1. Key Segment Analysis
    • 16.2. Regional Snapshot
    • 16.3. Europe Radioligand Therapies (RLT) Market Size Value (US$ Bn), Analysis, and Forecasts, 2021-2035
      • 16.3.1. Type
      • 16.3.2. Radioisotope
      • 16.3.3. Radiation Type
      • 16.3.4. Targeting Vector
      • 16.3.5. Product Class
      • 16.3.6. Cancer Type
      • 16.3.7. Distribution Channel
      • 16.3.8. End User
      • 16.3.9. Country
        • 16.3.9.1. Germany
        • 16.3.9.2. United Kingdom
        • 16.3.9.3. France
        • 16.3.9.4. Italy
        • 16.3.9.5. Spain
        • 16.3.9.6. Netherlands
        • 16.3.9.7. Nordic Countries
        • 16.3.9.8. Poland
        • 16.3.9.9. Russia & CIS
        • 16.3.9.10. Rest of Europe
    • 16.4. Germany Radioligand Therapies (RLT) Market
      • 16.4.1. Country Segmental Analysis
      • 16.4.2. Type
      • 16.4.3. Radioisotope
      • 16.4.4. Radiation Type
      • 16.4.5. Targeting Vector
      • 16.4.6. Product Class
      • 16.4.7. Cancer Type
      • 16.4.8. Distribution Channel
      • 16.4.9. End User
    • 16.5. United Kingdom Radioligand Therapies (RLT) Market
      • 16.5.1. Country Segmental Analysis
      • 16.5.2. Type
      • 16.5.3. Radioisotope
      • 16.5.4. Radiation Type
      • 16.5.5. Targeting Vector
      • 16.5.6. Product Class
      • 16.5.7. Cancer Type
      • 16.5.8. Distribution Channel
      • 16.5.9. End User
    • 16.6. France Radioligand Therapies (RLT) Market
      • 16.6.1. Country Segmental Analysis
      • 16.6.2. Type
      • 16.6.3. Radioisotope
      • 16.6.4. Radiation Type
      • 16.6.5. Targeting Vector
      • 16.6.6. Product Class
      • 16.6.7. Cancer Type
      • 16.6.8. Distribution Channel
      • 16.6.9. End User
    • 16.7. Italy Radioligand Therapies (RLT) Market
      • 16.7.1. Country Segmental Analysis
      • 16.7.2. Type
      • 16.7.3. Radioisotope
      • 16.7.4. Radiation Type
      • 16.7.5. Targeting Vector
      • 16.7.6. Product Class
      • 16.7.7. Cancer Type
      • 16.7.8. Distribution Channel
      • 16.7.9. End User
    • 16.8. Spain Radioligand Therapies (RLT) Market
      • 16.8.1. Country Segmental Analysis
      • 16.8.2. Type
      • 16.8.3. Radioisotope
      • 16.8.4. Radiation Type
      • 16.8.5. Targeting Vector
      • 16.8.6. Product Class
      • 16.8.7. Cancer Type
      • 16.8.8. Distribution Channel
      • 16.8.9. End User
    • 16.9. Netherlands Radioligand Therapies (RLT) Market
      • 16.9.1. Country Segmental Analysis
      • 16.9.2. Type
      • 16.9.3. Radioisotope
      • 16.9.4. Radiation Type
      • 16.9.5. Targeting Vector
      • 16.9.6. Product Class
      • 16.9.7. Cancer Type
      • 16.9.8. Distribution Channel
      • 16.9.9. End User
    • 16.10. Nordic Countries Radioligand Therapies (RLT) Market
      • 16.10.1. Country Segmental Analysis
      • 16.10.2. Type
      • 16.10.3. Radioisotope
      • 16.10.4. Radiation Type
      • 16.10.5. Targeting Vector
      • 16.10.6. Product Class
      • 16.10.7. Cancer Type
      • 16.10.8. Distribution Channel
      • 16.10.9. End User
    • 16.11. Poland Radioligand Therapies (RLT) Market
      • 16.11.1. Country Segmental Analysis
      • 16.11.2. Type
      • 16.11.3. Radioisotope
      • 16.11.4. Radiation Type
      • 16.11.5. Targeting Vector
      • 16.11.6. Product Class
      • 16.11.7. Cancer Type
      • 16.11.8. Distribution Channel
      • 16.11.9. End User
    • 16.12. Russia & CIS Radioligand Therapies (RLT) Market
      • 16.12.1. Country Segmental Analysis
      • 16.12.2. Type
      • 16.12.3. Radioisotope
      • 16.12.4. Radiation Type
      • 16.12.5. Targeting Vector
      • 16.12.6. Product Class
      • 16.12.7. Cancer Type
      • 16.12.8. Distribution Channel
      • 16.12.9. End User
    • 16.13. Rest of Europe Radioligand Therapies (RLT) Market
      • 16.13.1. Country Segmental Analysis
      • 16.13.2. Type
      • 16.13.3. Radioisotope
      • 16.13.4. Radiation Type
      • 16.13.5. Targeting Vector
      • 16.13.6. Product Class
      • 16.13.7. Cancer Type
      • 16.13.8. Distribution Channel
      • 16.13.9. End User
  • 17. Asia Pacific Radioligand Therapies (RLT) Market Analysis
    • 17.1. Key Segment Analysis
    • 17.2. Regional Snapshot
    • 17.3. Asia Pacific Radioligand Therapies (RLT) Market Size Value (US$ Bn), Analysis, and Forecasts, 2021-2035
      • 17.3.1. Type
      • 17.3.2. Radioisotope
      • 17.3.3. Radiation Type
      • 17.3.4. Targeting Vector
      • 17.3.5. Product Class
      • 17.3.6. Cancer Type
      • 17.3.7. Distribution Channel
      • 17.3.8. End User
      • 17.3.9. Country
        • 17.3.9.1. China
        • 17.3.9.2. India
        • 17.3.9.3. Japan
        • 17.3.9.4. South Korea
        • 17.3.9.5. Australia and New Zealand
        • 17.3.9.6. Indonesia
        • 17.3.9.7. Malaysia
        • 17.3.9.8. Thailand
        • 17.3.9.9. Vietnam
        • 17.3.9.10. Rest of Asia Pacific
    • 17.4. China Radioligand Therapies (RLT) Market
      • 17.4.1. Country Segmental Analysis
      • 17.4.2. Type
      • 17.4.3. Radioisotope
      • 17.4.4. Radiation Type
      • 17.4.5. Targeting Vector
      • 17.4.6. Product Class
      • 17.4.7. Cancer Type
      • 17.4.8. Distribution Channel
      • 17.4.9. End User
    • 17.5. India Radioligand Therapies (RLT) Market
      • 17.5.1. Country Segmental Analysis
      • 17.5.2. Type
      • 17.5.3. Radioisotope
      • 17.5.4. Radiation Type
      • 17.5.5. Targeting Vector
      • 17.5.6. Product Class
      • 17.5.7. Cancer Type
      • 17.5.8. Distribution Channel
      • 17.5.9. End User
    • 17.6. Japan Radioligand Therapies (RLT) Market
      • 17.6.1. Country Segmental Analysis
      • 17.6.2. Type
      • 17.6.3. Radioisotope
      • 17.6.4. Radiation Type
      • 17.6.5. Targeting Vector
      • 17.6.6. Product Class
      • 17.6.7. Cancer Type
      • 17.6.8. Distribution Channel
      • 17.6.9. End User
    • 17.7. South Korea Radioligand Therapies (RLT) Market
      • 17.7.1. Country Segmental Analysis
      • 17.7.2. Type
      • 17.7.3. Radioisotope
      • 17.7.4. Radiation Type
      • 17.7.5. Targeting Vector
      • 17.7.6. Product Class
      • 17.7.7. Cancer Type
      • 17.7.8. Distribution Channel
      • 17.7.9. End User
    • 17.8. Australia and New Zealand Radioligand Therapies (RLT) Market
      • 17.8.1. Country Segmental Analysis
      • 17.8.2. Type
      • 17.8.3. Radioisotope
      • 17.8.4. Radiation Type
      • 17.8.5. Targeting Vector
      • 17.8.6. Product Class
      • 17.8.7. Cancer Type
      • 17.8.8. Distribution Channel
      • 17.8.9. End User
    • 17.9. Indonesia Radioligand Therapies (RLT) Market
      • 17.9.1. Country Segmental Analysis
      • 17.9.2. Type
      • 17.9.3. Radioisotope
      • 17.9.4. Radiation Type
      • 17.9.5. Targeting Vector
      • 17.9.6. Product Class
      • 17.9.7. Cancer Type
      • 17.9.8. Distribution Channel
      • 17.9.9. End User
    • 17.10. Malaysia Radioligand Therapies (RLT) Market
      • 17.10.1. Country Segmental Analysis
      • 17.10.2. Type
      • 17.10.3. Radioisotope
      • 17.10.4. Radiation Type
      • 17.10.5. Targeting Vector
      • 17.10.6. Product Class
      • 17.10.7. Cancer Type
      • 17.10.8. Distribution Channel
      • 17.10.9. End User
    • 17.11. Thailand Radioligand Therapies (RLT) Market
      • 17.11.1. Country Segmental Analysis
      • 17.11.2. Type
      • 17.11.3. Radioisotope
      • 17.11.4. Radiation Type
      • 17.11.5. Targeting Vector
      • 17.11.6. Product Class
      • 17.11.7. Cancer Type
      • 17.11.8. Distribution Channel
      • 17.11.9. End User
    • 17.12. Vietnam Radioligand Therapies (RLT) Market
      • 17.12.1. Country Segmental Analysis
      • 17.12.2. Type
      • 17.12.3. Radioisotope
      • 17.12.4. Radiation Type
      • 17.12.5. Targeting Vector
      • 17.12.6. Product Class
      • 17.12.7. Cancer Type
      • 17.12.8. Distribution Channel
      • 17.12.9. End User
    • 17.13. Rest of Asia Pacific Radioligand Therapies (RLT) Market
      • 17.13.1. Country Segmental Analysis
      • 17.13.2. Type
      • 17.13.3. Radioisotope
      • 17.13.4. Radiation Type
      • 17.13.5. Targeting Vector
      • 17.13.6. Product Class
      • 17.13.7. Cancer Type
      • 17.13.8. Distribution Channel
      • 17.13.9. End User
  • 18. Middle East Radioligand Therapies (RLT) Market Analysis
    • 18.1. Key Segment Analysis
    • 18.2. Regional Snapshot
    • 18.3. Middle East Radioligand Therapies (RLT) Market Size Value (US$ Bn), Analysis, and Forecasts, 2021-2035
      • 18.3.1. Type
      • 18.3.2. Radioisotope
      • 18.3.3. Radiation Type
      • 18.3.4. Targeting Vector
      • 18.3.5. Product Class
      • 18.3.6. Cancer Type
      • 18.3.7. Distribution Channel
      • 18.3.8. End User
      • 18.3.9. Country
        • 18.3.9.1. Turkey
        • 18.3.9.2. UAE
        • 18.3.9.3. Saudi Arabia
        • 18.3.9.4. Israel
        • 18.3.9.5. Rest of Middle East
    • 18.4. Turkey Radioligand Therapies (RLT) Market
      • 18.4.1. Country Segmental Analysis
      • 18.4.2. Type
      • 18.4.3. Radioisotope
      • 18.4.4. Radiation Type
      • 18.4.5. Targeting Vector
      • 18.4.6. Product Class
      • 18.4.7. Cancer Type
      • 18.4.8. Distribution Channel
      • 18.4.9. End User
    • 18.5. UAE Radioligand Therapies (RLT) Market
      • 18.5.1. Country Segmental Analysis
      • 18.5.2. Type
      • 18.5.3. Radioisotope
      • 18.5.4. Radiation Type
      • 18.5.5. Targeting Vector
      • 18.5.6. Product Class
      • 18.5.7. Cancer Type
      • 18.5.8. Distribution Channel
      • 18.5.9. End User
    • 18.6. Saudi Arabia Radioligand Therapies (RLT) Market
      • 18.6.1. Country Segmental Analysis
      • 18.6.2. Type
      • 18.6.3. Radioisotope
      • 18.6.4. Radiation Type
      • 18.6.5. Targeting Vector
      • 18.6.6. Product Class
      • 18.6.7. Cancer Type
      • 18.6.8. Distribution Channel
      • 18.6.9. End User
    • 18.7. Israel Radioligand Therapies (RLT) Market
      • 18.7.1. Country Segmental Analysis
      • 18.7.2. Type
      • 18.7.3. Radioisotope
      • 18.7.4. Radiation Type
      • 18.7.5. Targeting Vector
      • 18.7.6. Product Class
      • 18.7.7. Cancer Type
      • 18.7.8. Distribution Channel
      • 18.7.9. End User
    • 18.8. Rest of Middle East Radioligand Therapies (RLT) Market
      • 18.8.1. Country Segmental Analysis
      • 18.8.2. Type
      • 18.8.3. Radioisotope
      • 18.8.4. Radiation Type
      • 18.8.5. Targeting Vector
      • 18.8.6. Product Class
      • 18.8.7. Cancer Type
      • 18.8.8. Distribution Channel
      • 18.8.9. End User
  • 19. Africa Radioligand Therapies (RLT) Market Analysis
    • 19.1. Key Segment Analysis
    • 19.2. Regional Snapshot
    • 19.3. Africa Radioligand Therapies (RLT) Market Size Value (US$ Bn), Analysis, and Forecasts, 2021-2035
      • 19.3.1. Type
      • 19.3.2. Radioisotope
      • 19.3.3. Radiation Type
      • 19.3.4. Targeting Vector
      • 19.3.5. Product Class
      • 19.3.6. Cancer Type
      • 19.3.7. Distribution Channel
      • 19.3.8. End User
      • 19.3.9. Country
        • 19.3.9.1. South Africa
        • 19.3.9.2. Egypt
        • 19.3.9.3. Nigeria
        • 19.3.9.4. Algeria
        • 19.3.9.5. Rest of Africa
    • 19.4. South Africa Radioligand Therapies (RLT) Market
      • 19.4.1. Country Segmental Analysis
      • 19.4.2. Type
      • 19.4.3. Radioisotope
      • 19.4.4. Radiation Type
      • 19.4.5. Targeting Vector
      • 19.4.6. Product Class
      • 19.4.7. Cancer Type
      • 19.4.8. Distribution Channel
      • 19.4.9. End User
    • 19.5. Egypt Radioligand Therapies (RLT) Market
      • 19.5.1. Country Segmental Analysis
      • 19.5.2. Type
      • 19.5.3. Radioisotope
      • 19.5.4. Radiation Type
      • 19.5.5. Targeting Vector
      • 19.5.6. Product Class
      • 19.5.7. Cancer Type
      • 19.5.8. Distribution Channel
      • 19.5.9. End User
    • 19.6. Nigeria Radioligand Therapies (RLT) Market
      • 19.6.1. Country Segmental Analysis
      • 19.6.2. Type
      • 19.6.3. Radioisotope
      • 19.6.4. Radiation Type
      • 19.6.5. Targeting Vector
      • 19.6.6. Product Class
      • 19.6.7. Cancer Type
      • 19.6.8. Distribution Channel
      • 19.6.9. End User
    • 19.7. Algeria Radioligand Therapies (RLT) Market
      • 19.7.1. Country Segmental Analysis
      • 19.7.2. Type
      • 19.7.3. Radioisotope
      • 19.7.4. Radiation Type
      • 19.7.5. Targeting Vector
      • 19.7.6. Product Class
      • 19.7.7. Cancer Type
      • 19.7.8. Distribution Channel
      • 19.7.9. End User
    • 19.8. Rest of Africa Radioligand Therapies (RLT) Market
      • 19.8.1. Country Segmental Analysis
      • 19.8.2. Type
      • 19.8.3. Radioisotope
      • 19.8.4. Radiation Type
      • 19.8.5. Targeting Vector
      • 19.8.6. Product Class
      • 19.8.7. Cancer Type
      • 19.8.8. Distribution Channel
      • 19.8.9. End User
  • 20. South America Radioligand Therapies (RLT) Market Analysis
    • 20.1. Key Segment Analysis
    • 20.2. Regional Snapshot
    • 20.3. South America Radioligand Therapies (RLT) Market Size Value (US$ Bn), Analysis, and Forecasts, 2021-2035
      • 20.3.1. Type
      • 20.3.2. Radioisotope
      • 20.3.3. Radiation Type
      • 20.3.4. Targeting Vector
      • 20.3.5. Product Class
      • 20.3.6. Cancer Type
      • 20.3.7. Distribution Channel
      • 20.3.8. End User
      • 20.3.9. Country
        • 20.3.9.1. Brazil
        • 20.3.9.2. Argentina
        • 20.3.9.3. Rest of South America
    • 20.4. Brazil Radioligand Therapies (RLT) Market
      • 20.4.1. Country Segmental Analysis
      • 20.4.2. Type
      • 20.4.3. Radioisotope
      • 20.4.4. Radiation Type
      • 20.4.5. Targeting Vector
      • 20.4.6. Product Class
      • 20.4.7. Cancer Type
      • 20.4.8. Distribution Channel
      • 20.4.9. End User
    • 20.5. Argentina Radioligand Therapies (RLT) Market
      • 20.5.1. Country Segmental Analysis
      • 20.5.2. Type
      • 20.5.3. Radioisotope
      • 20.5.4. Radiation Type
      • 20.5.5. Targeting Vector
      • 20.5.6. Product Class
      • 20.5.7. Cancer Type
      • 20.5.8. Distribution Channel
      • 20.5.9. End User
    • 20.6. Rest of South America Radioligand Therapies (RLT) Market
      • 20.6.1. Country Segmental Analysis
      • 20.6.2. Type
      • 20.6.3. Radioisotope
      • 20.6.4. Radiation Type
      • 20.6.5. Targeting Vector
      • 20.6.6. Product Class
      • 20.6.7. Cancer Type
      • 20.6.8. Distribution Channel
      • 20.6.9. End User
  • 21. Key Players/ Company Profile
    • 21.1. Actinium Pharmaceuticals, Inc.
      • 21.1.1. Company Details/ Overview
      • 21.1.2. Company Financials
      • 21.1.3. Key Customers and Competitors
      • 21.1.4. Business/ Industry Portfolio
      • 21.1.5. Product Portfolio/ Specification Details
      • 21.1.6. Pricing Data
      • 21.1.7. Strategic Overview
      • 21.1.8. Recent Developments
    • 21.2. AstraZeneca
    • 21.3. Bayer AG
    • 21.4. Bristol Myers Squibb
    • 21.5. Clarity Pharmaceuticals
    • 21.6. Curium Pharma Ltd.
    • 21.7. Eli Lilly and Company
    • 21.8. Perspective Therapeutics
    • 21.9. ITM Isotope Technologies Munich SE
    • 21.10. Lantheus Holdings
    • 21.11. Novartis AG
    • 21.12. POINT Biopharma Global Inc.
    • 21.13. RadioMedix Inc.
    • 21.14. Telix Pharmaceuticals Limited
    • 21.15. Y-mAbs Therapeutics, Inc.
    • 21.16. Other Key Players

 

Note* - This is just tentative list of players. While providing the report, we will cover more number of players based on their revenue and share for each geography

Get PDF
PRICING DETAILS
USD 4150
USD 5950
USD 7750
Related Report  
YOU MAY ALSO LIKE
Algae Protein Market by Source Type, Form, Protein Content, Production Method, Nature, Extraction Technology, Grade, End-Use Industry, and Geography
Alternative Protein Market by Source/Type, Form, Product Type, Processing Technology, Distribution Channel, Protein Content, End-users, and Geography
Astaxanthin Market by Source/Origin, Form, Grade/Purity Level, Concentration Level, Production Technology, End-users, Distribution Channel, Packaging Type, and Geography
Discount On Multiple Reports

Where did We Help Most?

Custom Market Research Services

We will customise the research for you, in case the report listed above does not meet your requirements.

Get 10% Free Customisation